Safety of pembrolizumab while commencing treatment for hepatitis C with Harvoni (ledipasvir and sofosbuvir)

Intern Med J. 2018 Dec;48(12):1542-1543. doi: 10.1111/imj.14131.

Authors

Lalitha L Menon¹, Beatrice Chin¹, Muhammad A Khattak^{1

2

3}

Affiliations

¹ Department of Oncology, Fiona Stanley Hospital, Perth, Western Australia, Australia.
² Department of Medical Oncology, University of Western Australia, Perth, Western Australia, Australia.
³ School of Medical and Health Sciences, Edith Cowan University, Perth, Western Australia, Australia.

PMID: 30517998
DOI: 10.1111/imj.14131

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antibodies, Monoclonal, Humanized / administration & dosage*
Antineoplastic Agents, Immunological / administration & dosage
Antiviral Agents / administration & dosage
Benzimidazoles / administration & dosage*
Clinical Decision-Making
Drug Therapy, Combination / methods
Fluorenes / administration & dosage*
Hepacivirus / drug effects
Hepacivirus / isolation & purification
Hepatitis C, Chronic* / complications
Hepatitis C, Chronic* / diagnosis
Hepatitis C, Chronic* / drug therapy
Humans
Male
Melanoma* / complications
Melanoma* / drug therapy
Melanoma* / pathology
Middle Aged
Neoplasm Staging
Sofosbuvir
Treatment Outcome
Uridine Monophosphate / administration & dosage
Uridine Monophosphate / analogs & derivatives*

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
Antiviral Agents
Benzimidazoles
Fluorenes
ledipasvir, sofosbuvir drug combination
pembrolizumab
Uridine Monophosphate
Sofosbuvir